StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.30−0.02 (-0.60%)

Close on Nov 18, 2026Market cap $263.35MP/E –Yield –

Prelude Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Prelude Therapeutics's price to sales ratio was 14.2× on Nov 11, 2026, against 12.2× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202614.2×−6.8
2025Dec 31, 202521.0×–

More Prelude Therapeutics figures

See a number that looks wrong?